These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 2975535

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. K-lymphocytes (killer-cells) in Crohn's disease and acute virus B-hepatitis.
    Eckhardt R, Kloos P, Dierich MP, Meyer zum Büschenfelde KH.
    Gut; 1977 Dec; 18(12):1010-6. PubMed ID: 304825
    [Abstract] [Full Text] [Related]

  • 45. Increased number of CD4 cells able to bind to natural killer cell targets in the peripheral blood of AIDS related complex patients.
    Barnaba V, Valesini G, Gattamelata G, Benvenuto R, Velardi A, Balsano F.
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):369-76. PubMed ID: 2968260
    [Abstract] [Full Text] [Related]

  • 46. [Use of antilymphocytic gamma globulin to monitor the course of viral hepatitis B].
    Gerasun BA, Burlev VA, Danileĭchenko IV.
    Lab Delo; 1989 Mar; (1):46-9. PubMed ID: 2468027
    [Abstract] [Full Text] [Related]

  • 47. Treatment of patients with Langerhans cell histiocytosis with vindesine.
    Hirose M, Ishimoto K, Ninomiya T, Kuroda Y.
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):421-2. PubMed ID: 8888759
    [No Abstract] [Full Text] [Related]

  • 48. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures.
    Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL.
    Arch Gen Psychiatry; 1990 Aug; 47(8):729-35. PubMed ID: 2143062
    [Abstract] [Full Text] [Related]

  • 49. A case of malignant haemangioendothelioma treated with recombinant interleukin-2.
    Ansai S, Goto K, Aoki T, Hozumi Y, Aso K.
    Clin Exp Dermatol; 1993 Sep; 18(5):470-5. PubMed ID: 8252775
    [Abstract] [Full Text] [Related]

  • 50. Pathogenesis of chronic active hepatitis B.
    Thomas H.
    J Gastroenterol Hepatol; 1991 Sep; 6 Suppl 1():4-6. PubMed ID: 1721554
    [No Abstract] [Full Text] [Related]

  • 51. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
    Whittington R, Faulds D.
    Drugs; 1993 Sep; 46(3):446-514. PubMed ID: 7693434
    [Abstract] [Full Text] [Related]

  • 52. Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes.
    Haak-Frendscho M, Young KM, Czuprynski CJ.
    Infect Immun; 1989 Oct; 57(10):3014-21. PubMed ID: 2789191
    [Abstract] [Full Text] [Related]

  • 53. Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
    Yamaguchi S, Onji M, Kondoh H, Miyaoka H, Ohta Y.
    Clin Exp Immunol; 1988 Oct; 74(1):1-6. PubMed ID: 2975535
    [Abstract] [Full Text] [Related]

  • 54. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.
    Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G.
    J Immunol; 1994 Mar 15; 152(6):3074-87. PubMed ID: 7511637
    [Abstract] [Full Text] [Related]

  • 55. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2865-75. PubMed ID: 2993418
    [Abstract] [Full Text] [Related]

  • 56. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 57. Chronic hepatitis C in the advanced adult and elderly subjects.
    Gattoni A, Parlato A, Vangieri B, Bresciani M, Petraccaro M.
    Minerva Gastroenterol Dietol; 2009 Jun 15; 55(2):145-57. PubMed ID: 19305374
    [Abstract] [Full Text] [Related]

  • 58. Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
    Yamaguchi S, Onji M, Kondoh H, Miyaoka H, Ohta Y.
    Clin Exp Immunol; 1988 Oct 15; 74(1):1-6. PubMed ID: 2975535
    [Abstract] [Full Text] [Related]

  • 59. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.
    Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G.
    J Immunol; 1994 Mar 15; 152(6):3074-87. PubMed ID: 7511637
    [Abstract] [Full Text] [Related]

  • 60. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2865-75. PubMed ID: 2993418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.